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Previous randomized controlled trials (RCTs) and meta-analyses evaluated the efficacy and safety 
of adjunctive corticosteroids for community-acquired pneumonia (CAP). However, the results from 
them had large discrepancies. The eligibility criteria for the current meta-analysis were original 
RCTs written in English as a full article that evaluated adjunctive systemic corticosteroids adding on 
antibiotic therapy targeting typical and/or atypical pathogen for treating hospitalized human CAP 
cases. Four investigators independently searched for eligible articles through PubMed, Embase, 
and Cochrane databases. Random model was used. The heterogeneity among original studies and 
subgroups was evaluated with the I2 statistics. Of 54 articles that met the preliminary criteria, we 
found 10 eligible RCTs comprising 1780 cases. Our analyses revealed following pooled values by 
corticosteroids. OR for all-cause death: 0.80 (95% confidence interval (95% CI) 0.53–1.21) from all 
studies; 0.41 (95% CI 0.19–0.90) from severe-case subgroup; 0.21 (95% CI 0.0–0.74) from intensive 
care unit (ICU) subgroup. Length of ICU stay: −1.30 days (95% CI (−3.04)−0.44). Length of hospital 
stay: −0.98 days (95% CI (−1.26)–(−0.71)). Length to clinical stability: −1.16 days (95% CI (−1.73)–
(−0.58)). Serious complications do not seem to largely increase by steroids. In conclusion, adjunctive 
systemic corticosteroids for hospitalized patients with CAP seems preferred strategies.
Respiratory infection including pneumonia is the third-leading cause of death worldwide1–3. A majority of 
patients with pneumonia presents with community-acquired pneumonia (CAP). Despite recent advances 
in diagnostic methods and antibiotic treatment, the overall mortality rate of CAP remains approximately 
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5–20%. Although it had been considered that corticosteroids may exacerbate the control of infectious dis-
ease, the recent consensus is that adjunctive corticosteroids added to antibiotic treatment is a reasonable 
strategy when treating patients with critical infectious diseases namely bacterial meningitis, sepsis and 
septic shock4,5. The therapeutic efficacy of corticosteroids may be based on down regulation of excessive 
inflammation via controlling cytokines. Similarly, corticosteroids attenuate the action of many cytokines 
involved in the inflammatory response associated with CAP6. Thus, the use of adjunctive corticosteroids 
is an appealing option for CAP treatment and has been evaluated in many randomized controlled trials 
(RCTs) for decades7–16. However, the results from previously reported RCTs that evaluated the impact 
of systemic corticosteroids for CAP had large discrepancies with each other. In addition, meta-analyses 
of these RCTs did not reach complete agreement12–22 (Table  1). Furthermore, a middle-scale and a 
large scale RCTs published in 2015 were not included in these published meta-analysis15,16. Moreover, 
some recent studies were focused on the time to clinical stability11,15,16, however, none of the previous 
meta-analyses evaluated the time to clinical stability. Therefore, we believe an updated meta-analysis is 
required. The aim of this study was to evaluate the efficacy and safety of adjunctive corticosteroids for 
patients with CAP.
Methods
Study search. Institutional review board approval and patient consent were not required because of 
the review nature of this study.
Four investigators independently searched for eligible articles as of March 2015 through PubMed, 
Embase, and Cochrane databases. One reviewer used the following search formula for PubMed: “(com-
munity acquired pneumonia) AND (RCT OR randomized) AND (steroid OR corticosteroid OR cortisol 
OR methylprednisolone OR prednisolone OR dexamethasone OR hydrocortisone)”.
The eligibility criteria for the current meta-analysis were original RCTs written in English as a full 
article that evaluated adjunctive systemic corticosteroids adding on antibiotic therapy targeting typi-
cal and/or atypical pathogen for treating hospitalized human CAP cases. Any types, any doses, and 
any durations of systemic corticosteroids were allowed. Articles focusing on an immunocompromised 
host, inhaled corticosteroid, nosocomial pneumonia, child cases, or specified pathogens were excluded. 
Included articles had to evaluate at least one of the outcomes mentioned below.
Outcomes. Mortality that can be expressed as an odds ratio (OR) was evaluated. If two or more 
types of mortality were descripted, the mortality of longer duration was selected. For example, 90-day 
mortality was preferred followed by 30-day, in-hospital, intensive care unit (ICU) mortality, in that order.
Author, year






Salluh, 200817 Severe CAP 3 RCTs and 1 cohort study 415
Not recommending CS for 
severe CAP.
Siempos, 200818
CAP with any severity (only 
studies for severe CAP were 
found)
4 RCTs 189
Limited data suggested that CS 
lowers mortality and shortens 
length of hospital stay for 
severe CAP.
Chen, 201119
Any type of pneumonia. 
including nosocomial and child 
pneumonia
6 RCTs (2 for 
child, 1 for 
inhaled CS.
437
CS are generally beneficial for 
pneumonia. Evidence is lack-
ing to make recommendation.
Nie, 201220 CAP with any severity. 9 RCTs 1001
CS is not recommended for 
CAP in general. However, 
it is possible that CS lower 
mortality from severe CAP 
and that CS > 6 d may be more 
beneficial than CS ≤ 5 d.
Cheng, 201321 Severe CAP 4 RCTs 264
Limited evidence suggests 
that CS lowers mortality from 
severe CAP.
Shafiq, 201322 CAP requiring admission. 8 RCTs 1119
CS shortens length of hos-
pital stay. CS does not lower 
mortality.
Current study CAP requiring admission. 10 RCTs 1780
CS shortens length of hospital 
stay for CAP. CS shortens 
length to clinical stability for 
CAP. CS lowers mortality for 
CAP in intensive care unit. 
CS > 6 d is not more beneficial 
than CS ≤ 5 d.
Table 1.  Systematic reviews and meta-analyses evaluating adjunctive corticosteroids for community-
acquired pneumonia. [ ]: reference number. RCT: randomized controlled trial. CS: corticosteroids. CAP: 
community-acquired pneumonia.
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Length of ICU stay, length of hospital stay, and length to clinical stability in the form of a hazard ratio 
(HR) or mean difference were also meta-analyzed.
Statistics. If both an intention-to-treat analysis and per-protocol-analysis were conducted, we adopted 
the result from the intention-to-treat analysis. Throughout the meta-analyses random model, not fixed 
model, was used23. If necessary, mean and standard deviation (SD) of length of ICU stay, length of hos-
pital stay, and length to clinical stability were estimated from median, range, or interquartile range of 
them23,24.
The heterogeneity among original studies and subgroups was evaluated with the I2 statistics whereby 
I2 = 0% indicates no heterogeneity, 0% < I2 < 25% indicates the least heterogeneity, 25% ≤ I2 < 50% indi-
cates mild heterogeneity, 50% ≤ I2 < 75% indicates moderate heterogeneity, and 75% ≤ I2 indicates strong 
heterogeneity25.
Results
Study search. Of 54 articles that met the preliminary criteria, we found 10 eligible RCTs7–16 (Fig. 1).
These 10 RCTs include four single-facility trials and six multiple-facility trials. Concerning blinding, 
seven were blinded for both physicians and patients, one was blinded for only patients, and two were 
not blinded. Prednisolone (PSL), hydrocortisone (HC), methylprednisolone (mPSL), and dexamethasone 
(DEX) were administered for four, three, two, and one trial, respectively. One study used HC bolus only, 
while the others administered corticosteroids for three to nine days. The numbers of cases included in 
each study ranged from 30 to 785 with a median of 100. The average ages of patients in each study were 
early 60 s for seven studies. In each study, 48–73% of cases were men (Table 2). Each study had a low or 
unclear risk of bias (Table 3).
Mortality. All included studies, except for one reported mortality. A report from Mikami did not 
report data concerning mortality10. Moreover, no response to our e-mail inquiry was obtained from the 
author. Thus, data concerning mortality in this report was derived from a systematic review by Salluh 
et al.17.
Figure 1. PRISMA diagram. 
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Pooled OR for all-cause death by adjunctive corticosteroids estimated from the results of 10 RCTs 
was 0.80 (95% confidence interval (95% CI) 0.53–1.21, P = 0.29. I2 = 0%, P for heterogeneity = 0.46) 
(Fig. 2A).
Because previous meta-analyses suggested that systemic corticosteroids improve the mortality only 
for severe CAP17,20,21, we performed a subgroup sensitive analysis dividing studies into those with severe 
case only and those not limited to severe cases. Previous meta-analyses used different criteria of “severe 
pneumonia17,20,21”. Here, we selected studies that clearly indicated “severe CAP” in the title and/or abstract 
and studies limited to ICU cases. We observed a strong subgroup difference between the results from 
five trials not limited to severe cases and those from five trials limited to severe cases (I2 = 73.5%, P for 
subgroup heterogeneity = 0.05) (Fig. 2A). Five RCTs limited to severe cases yielded a pooled OR of 0.41 
(95% CI 0.19–0.90, P = 0.03. I2 = 0%, P for heterogeneity = 0.45) (Fig.  2A). In addition, we conducted 
another subgroup analysis dividing studies into those limited to ICU cases and those not limited to ICU 
cases. Again, we observed a strong subgroup difference (I2 = 79.7%, P for subgroup heterogeneity = 0.03). 
Three RCTs limited to ICU cases yielded a pooled OR of 0.21 (95% CI 0.06–0.74, P = 0.01. I2 = 0%, P for 
heterogeneity = 0.43) (Fig. 2B).
Since Nie et al. reported that CS > 6 d was more beneficial than CS ≤ 5 d20, we performed a sensitivity 
analysis. However, we could not find a significant subgroup OR difference between prolonged and short 
corticosteroids treatment for all-cause mortality. (I2 = 0%, P for subgroup heterogeneity = 0.99) (Fig. 2C).
Using data from the five trials limited to severe cases, the pooled risk difference for mortality was 
− 0.10 (95% CI –(0.21)–(− 0.00), P = 0.04). This pooled difference of − 0.10 was equivalent to a number 
needed to treat of 10 (Fig. 2D).
Length of ICU stay. A random-model meta-analysis using data from five RCTs indicated that length 





criteria Severity criteria Steroid regimen Antibiotics





McHardy 19727 Australia Not-blinded Single 12-
not at risk of 
dying within 
24 hour
PSL 20 mg/day 
for 7 d
Ampicillin 1 or 





Single-blinded Multi 18–70 ICU, BTS criteria severe
HC 10 mg/kg 
bolus
Cefotaxime based 
regimen 14 + 16 = 30 36 NS
Confalonieri 




ICU, ATS criteria 
severe
HC 200 mg 
bolus + 240 mg/
day for 7 d
Based on guide-
lines 23 + 23 = 46 64 70%










15 + 16 = 31 72 74%
Snijders 201011 Nether-lands Double-blinded Single 18- NS





104 + 109 = 213 64 58%
Fernández-Ser-
rano201112 Spain Double-blinded Single 18–75
P/F ratio < 300, 
Not ventilated at 
admission
mPSL 200 mg 
bolus + 80 mg/
day for 3 
days + 40 mg/
day for 3 
days + 20 mg/
ady for 3 days.
Ceftriaxone + Lev-
ofloxacin 22 + 23 = 45 64 67%
Meijvis 201113 Nether-lands Double-blinded Multi 18- Non-ICU






151 + 153 = 304 64 56%
Sabry 201114 Egypt Double-blinded Multi adult ICU Ventilated
HC 200 mg 
bolus + 300 mg/
day for 7 d
NS 40 + 40 = 80 62 73%
Blum 201515 Swizer-land Double-blinded Multi 18- NS
PSL 50 mg/day 
for 7 d
Based on guide-
lines 392 + 393 = 785 73 62%




index = V and 
CRP > 150 mg/L”
mPSL 1 mg/kg/
day for 5 d
Ceftriax-
on + Levofloxacin 
or + Azithromycin 
were preferred
61 + 59 = 120 65 62%
Table 2.  Characteristics of included randomized controlled trials. [ ]: reference number. ICU: intensive 
care unit. BTS: Brithsh Thoracic Society. ATS: American Thoracic Society. PORT PSL: prednisolone. mPSL: 
methylprednisolone. DEX: dexamethasone. HC: hydrocortisone d: day.
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McHardy 1972 Low Unclear(a) Unclear(b) High(c) Low Low Low Unclear
Marik 1993 Low Unclear(a) Low High(c) Low Low Unclear(f) Unclear
Confalonieri 2005 Low Low Low Low Low Low Unclear(f) Low
Mikami 2007 Low Unclear(a) Unclear(b) High(c) Low Unclear(e) Unclear(f) Unclear
Snijders 2010 Low Low Low Low Low Low Low Low
Fernández-S. 2011 Low Unclear(a) Low Low Unknown(d) Low Unclear(f) Low
Meijvis 2011 Low Low Low Low Low Low Low Low
Sabry 2011 Low Unclear(a) Low Low Low Low High(g) Unclear
Blum 2015 Low Low Low Low Low Low Low Low
Torres 2015 Low Unclear(a) Low Low Low Low Low Low
Table 3.  Risk of bias. (a) Not centralized randomization. (b) Open-label study. (c) Open-label or single-
blinded study. (d) 20% of cases were excluded after randomization and per-protocol analysis was conducted. 
(e) Mortality was not reported. (f) Considering relatively small sample size (n < 50), possible publication 
bias could not denied. (g) Insufficient description of methods and results.
Figure 2. Forrest plots. OR: odds ratio. HR: hazard ratio. 95% CI: 95% confidence interval. M-H: Mantel-
Haenzel. ICU: intensive care unit.
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a mean difference of − 1.30 days (95%CI (− 3.04)–0.44, P = 0.14. I2 = 25%, P for heterogeneity = 0.26) 
(Fig. 2E).
No study reported HR for length of ICU stay.
Length of hospital stay. Seven studies reported difference of length of hospital stay in days. Based 
on these data, the length of hospital stay was shorter in the steroid arm with a pooled mean difference 
of − 0.98 (95% CI (− 1.26)–(− 0.71), P < 0.001. I2 = 4%, P for heterogeneity = 0.39). We performed a 
sensitivity analysis comparing the result from a study by Blum et al. and those from the others because 
the study by Blum et al. had very large weight of 86.8%. However, there was no significant subgroup 
heterogeneity between them (I2 = 0%, P for subgroup heterogeneity = 0.85) (Fig. 2F).
When evaluated using HR for hospital discharge, the length in hospital stay was also shorter in the 
steroid arm with a pooled HR of 1.23 (95% CI 1.07–1.41, P = 0.003. I2 = 14%, P for heterogeneity = 0.32) 
(Fig. 2G).
Length to clinical stability. Length to clinical stability was evaluated in three recent studies. They 
yielded pooled difference of − 1.16 days (95% CI (− 1.73)–(− 0.58), P < 0.001. I2 = 43%, P for heteroge-
neity = 0.17) (Fig. 2H).
The same three studies yielded a pooled HR of 1.29 (95% CI 1.14–1.45, P < 0.001. I2 = 0%, P for 
heterogeneity = 0.55) (Fig. 2I).
Adverse effects. In this systematic review, we noticed that some reports described adverse effects. 
However, these data were not suitable for qualitative meta-analysis due to discrepancy of descriptive 
method.
Confalonieri et al. reported that major complication (steroid: 6/23 vs. placebo 18/23, P < 0.001) and 
delayed septic shock (steroid: 0/23 vs. placebo: 10/23, P < 0.001) were less frequently observed in the 
steroid arm9. Mikami et al. reported no significant difference in deterioration of glucose intolerance, 
electrolyte abnormalities, nor other adverse effects was observed10. Snijders et al. revealed that the overall 
adverse effect was not different in two arms (steroid: 63/104 vs. placebo: 72/109, P = 0.41)11. Meijvis et al. 
reported that hyperglycemia was more common in the steroid arm (steroid: 67/151 vs. placebo: 35/153, 
P < 0.001) but that the requirement for glucose-lowering treatment and superinfection were not signifi-
cantly different between arms13. Blum at al. wrote that overall adverse events were frequently observed in 
the steroid arm (steroid: 96/392 vs. placebo: 61/393, P < 0.001), and the difference was mainly attributed 
to the increase of hyperglycemia requiring new insulin (steroid: 76/392 vs. placebo: 43/393, P = 0.001)15. 
Torres et al. compared the incidence of six adverse effects including hyperglycemia but none differed 
significantly16.
In general, although patients in the steroid arm might have a higher risk for overall adverse events 
and hyperglycemia, serious complications do not seem to largely increase due to use of systemic steroids.
Discussion
This updated systematic review and meta-analysis had the largest sample size ever (Table  1). The key 
findings from this analysis are as follows: (i) corticosteroids shortens length of hospital stay for CAP, 
(ii) corticosteroids shortens length to clinical stability for CAP, and (iii) corticosteroids lowers mortality 
for severe CAP. Additionally, we revealed that the incidence of major complications was not greatly 
increased by systemic steroids, though quantitative synthesis was not feasible.
Inflammation is part of the complex biological response to harmful stimuli such as pathogens and 
damaged cells. This response is essential to control CAP. However, fulminant inflammation often results 
in organ failure. The rationale of using adjunctive systemic corticosteroids for CAP is to down-regulate 
excessive inflammation. Corticosteroids are very potent and by far the most frequently used type of 
immunosuppressant. The mechanism of corticosteroids is not fully clear; however, it is believed that 
corticosteroids switch off genes that encode pro-inflammatory cytokines and switch on genes that encode 
anti-inflammatory cytokines6. Based on our analysis, corticosteroids decreased mortality for severe/ICU 
CAP only. In this subgroup, merit of controlling systemic inflammation may overweight demerit of 
deteriorating innate body antibacterial action due to immunosuppressant.
Except for the OR for death, frequently used outcomes that we also evaluated in this study need be 
interpreted carefully. The length of hospital stay and ICU stay are often affected by non-pharmacological 
reasons, such as availability of ICU and non-ICU beds in a hospital. In this view, the time to clinical 
stability can evaluate more physiological aspects of a patient. However, some items included in the defi-
nition of clinical stability are known to be relieved by the administration of the systemic corticosteroids 
without direct relationship with the mortality26. For example, strong antipyretic effect of the corticos-
teroids obviously shortens the time to clinical stability. However, it is not clear whether the antipyretic 
effect can improve mortality and other outcomes. But then again, corticosteroids favored results for these 
uncertain outcomes, together with the decreased OR for death, made our results plausible.
The best corticosteroids regimen, for CAP is not clear. Nie et al. found that prolonged use of corti-
costeroids (> 5 days) was associated with a greater benefit compared with short course corticosteroids 
(≤ 5 days)20. However, this was not replicated in the current analysis. The length of the corticosteroids 
therapy used in the included trials was five days on average with a median of seven days (Table 2). Thus, 
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a 5–7 days treatment course seems reasonable for now. The best dosage of corticosteroids is also unclear. 
Most studies used HC 200–300 mg/day, PSL/mPSL 20–50 mg/day, or mPSL 1mg/kg/day (Table 2). Thus, 
a so-called low- or middle-dose of corticosteroids seems an acceptable choice in practice. Corticosteroids 
in these doses are also chosen for treatment of other common form of critical systematic inflammatory 
disease such as acute exacerbation of chronic obstructive pulmonary disease27, acute respiratory distress 
syndrome28, and septic shock29.
Some studies that were not included in this study have also revealed the efficacy of systematic cor-
ticosteroids for CAP. Garcia-Vidal et al. conducted a retrospective study with 308 severe CAP patients, 
which concluded that risk of death was reduced with adjusted OR of 0.28730. A cohort study in 2013 by 
Nagy et al. reported that the 5-day methylprednisolone therapy with imipenem was found to be effective 
in children with severe CAP31. Adjunctive systemic corticosteroids may be effective for CAP patients of 
any age.
Limitations of this study should be mentioned. First, we could not meta-analyze the data for adverse 
effects. Second, although four studies that evaluated the length of ICU stay constantly indicated the ten-
dency of a steroid-favored outcome, these results did not reach statistical significance probably due to 
lack of power. Third, we could not infer the impact of corticosteroids for outpatients with CAP. Forth, 
the best corticosteroids regimen could not be clarified. Lastly, our analysis could not directly explain why 
the adjunctive corticosteroids have different impact for mild and severe CAP.
In conclusion, although further RCTs focusing on severe CAP are anticipated, adjunctive systemic 
corticosteroids for hospitalized patients with CAP seem preferred strategies because this treatment short-
ens the length of hospital stay and the length to clinical stability without increasing severe adverse effect. 
In addition, adjunctive systemic corticosteroids lowers the mortality of severe CAP cases. Prolonged use 
of corticosteroids (> 5 days) was not more effective than a short course of corticosteroids (≤ 5 days). The 
best corticosteroids regimen is not clear, however, a middle dose of corticosteroids, for example PSL/
mPSL 40 mg/day to 1 mg/kg/day for 5–7 days seems a reasonable choice.
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